Top

International Journal of Clinical Oncology

Published in:

01-10-2011 | Case Report

Blue toe syndrome and sunitinib

Authors: Pieter G. Postema, Madelien V. Regeer, Paul R. van der Valk, Erik S. G. Stroes, Dick J. Richel

Published in: International Journal of Clinical Oncology | Issue 5/2011

Abstract

We present a patient with metastatic renal cell carcinoma treated with sunitinib, a multitargeted tyrosine kinase inhibitor. The patient experienced bilateral blue toe syndrome which we related to sunitinib use. Discontinuation of sunitinib to lower the patient’s prothrombotic state and increase the ability to form collaterals, together with the addition of low-molecular-weight heparin to treat the occluding thrombi, resulted in waning of the blue toe syndrome. This case adds to the accumulating evidence of possible untoward cardiovascular side effects that should be taken into consideration in patients on tyrosine kinase inhibitors such as sunitinib.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef

Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019PubMedCrossRef

Elice F, Rodeghiero F, Falanga A et al (2009) Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22:115–128PubMedCrossRef

Choueiri TK, Schutz FA, Je Y et al (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28:2280–2285PubMedCrossRef

Hirschmann JV, Raugi GJ (2009) Blue (or purple) toe syndrome. J Am Acad Dermatol 60:1–20PubMedCrossRef

Trousseau A (1868) Phlegmatia alba dolens. In: Trousseau A (ed) Clinique medicale de l’hotel-dieu de Paris. J.-B. Bailliere et Fils, Paris, pp 652–695

O’Connor B (1884) Symmetrical gangrene. Br Med J 1:460

Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110:1723–1729PubMedCrossRef

Title: Blue toe syndrome and sunitinib
Authors: Pieter G. Postema
Madelien V. Regeer
Paul R. van der Valk
Erik S. G. Stroes
Dick J. Richel
Publication date: 01-10-2011
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0153-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases

Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

Molecular mechanisms of liver metastasis

A case of primary uterine cervical neuroendocrine tumor with meningeal carcinomatosis confirmed by diagnostic imaging and autopsy

Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer